Merck’s oral HIV treatment meets main goal in late-stage study

(Reuters) -Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial.

The company said the treatment is a once-daily two-drug regimen of doravirine/islatravir that was non-inferior to a three-drug regimen in adults with HIV-1 infection who had not previously received antiretroviral therapy.

The Rahway, New Jersey-based company plans to present detailed findings from this trial at a future medical meeting and to submit applications including these data to health authorities.

(Reporting by Sneha S K; Editing by Tasim Zahid)